$PDSB News

PDS Biotech (NASDAQ:PDSB) Posts Narrower Q1 Loss, Pre-Market Rises Over 5%

PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript

PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript

PDS Biotechnology Q1 EPS $(0.13) Beats $(0.15) Estimate

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $15 Price Target

Why Is PDS Biotechnology Stock Gaining Wednesday?

PDS Biotechnology shares are trading higher after the company announced the publication of clinical and immunological biomarker data from Stage 1 of a Phase 2 trial evaluating its tumor-targeted IL-12 immunocytokine, PDS01ADC, in the March 10, 2026 issue of Journal of Clinical Oncology Oncology Advances.

PDS Biotechnology shares are trading higher after the company announced the publication of clinical and immunological biomarker data from Stage 1 of a Phase 2 trial evaluating its tumor-targeted IL-12 immunocytokine, PDS01ADC, in the March 10, 2026 issue of Journal of Clinical Oncology Oncology Advances.

PDS Biotechnology Announces Publication Of Clinical And Immunological Biomarker Data From Stage 1 Of Phase 2 Trial Evaluating Its Tumor-Targeted IL-12 Immunocytokine, PDS01ADC, In March 10 Issue Of JCO Oncology Advances

PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript

PDS Biotechnology Q4 EPS $(0.14) Beats $(0.20) Estimate

PDS Biotechnology Reports Early Positive Results In Cancer Study, Tweaks Late-Stage Cancer Trial To Speed Up Potential Approval

PDS Biotechnology Corp Reported FY25 EPS Loss Of $0.74/Share, Cash Balance Of $26.7M

PDS Biotechnology Receives Nasdaq Noncompliance Notice, Gets Time Through Aug. 24 To Regain Compliance

PDS Biotechnology Adopts Amended Protocol To Its Phase 3 VERSATILE-003 Clinical Study

PDS Biotechnology Presents Results Of National Cancer Institute-Led Study Of Investigational Interleukin-12 Tumor Targeted Immunocytokine, PDS01ADC, At AACR Special Conference

PDS Biotechnology Announces U.S. Patent Office Issues Notice Of Allowance For Its PDS0101 Asset

PDS Biotechnology Submits Protocol Amendment To FDA For Its Phase 3 VERSATILE-003 Study

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

PDS Biotechnology shares are trading higher after the company announced a new composition of matter patent for PDS0101 in Japan.